Cargando…
Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir
Orthopoxviruses, including smallpox, monkeypox and molluscipox, pose risks to human health through bioterrorist acts or natural transmission. There is no approved therapy for orthopoxvirus infections; however, cidofovir (CDV) has been approved as an investigational new drug for emergency treatment o...
Autores principales: | Quenelle, Debra C, Collins, Deborah J, Kern, Earl R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528221/ https://www.ncbi.nlm.nih.gov/pubmed/15196818 http://dx.doi.org/10.1016/j.antiviral.2004.02.003 |
Ejemplares similares
-
Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246
por: Quenelle, Debra C., et al.
Publicado: (2010) -
Isolation and characterization of cidofovir resistant vaccinia viruses
por: Becker, Marie N, et al.
Publicado: (2008) -
Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir
por: Bray, Mike, et al.
Publicado: (2002) -
Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine
por: Prichard, Mark N, et al.
Publicado: (2008) -
Vaccinia virus and Cowpox virus are not susceptible to the interferon-induced antiviral protein MxA
por: Lorenzo, María M., et al.
Publicado: (2017)